Gapping up
In reaction to strong earnings/guidance: TSL +9%, FN +5%, CMCM +4.7%, NNA +4.1%, HTHT +1%, HD +0.8%
Other news: NURO +31.2% (reports positive clinical results for its quell wearable pain relief device), OMER +13.4% (announces additional 'positive data' in its Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies), ESPR +9.9% ( Provides Update on the ETC-1002 Development Program Following End-of-Phase 2 Meeting With FDA; Company on Track to Initiate Phase 3 Development Program in 2015), QTM +6.5% (Private Capital Management disclosed 6.52% active stake in 13D filing), AVEO +4.7% (cont strength), CSIQ +3.4% (in symp with TSL earnings), SGEN +2.9% (Announces FDA Regular Approval of ADCETRIS), IQNT +2.2% (enters three-year agreement with T-Mobile US (TMUS) for VoIP; raises FY15 rev guidance), IMMU +1.6% (issued a U.S. Patent for a new patent family 'Antibody-SN-38 Immunoconjugates with a CL2A Linker'), ONE +1.5% ( Zilkha Investments discloses 9.7% active stake in 13D filing; may attempt to influence the management of the Company ), JCP +0.9% (favorable commentary on Monday's Mad Money)
Analyst comments: JUNO +2.4% ( initiated with a Outperform at FBR Capital; tgt $73), NNBR +2.2% (initiated with a Buy at Stifel), AEO +0.8% (initiated with a Outperform at Wolfe Research
)
In reaction to strong earnings/guidance: TSL +9%, FN +5%, CMCM +4.7%, NNA +4.1%, HTHT +1%, HD +0.8%
Other news: NURO +31.2% (reports positive clinical results for its quell wearable pain relief device), OMER +13.4% (announces additional 'positive data' in its Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies), ESPR +9.9% ( Provides Update on the ETC-1002 Development Program Following End-of-Phase 2 Meeting With FDA; Company on Track to Initiate Phase 3 Development Program in 2015), QTM +6.5% (Private Capital Management disclosed 6.52% active stake in 13D filing), AVEO +4.7% (cont strength), CSIQ +3.4% (in symp with TSL earnings), SGEN +2.9% (Announces FDA Regular Approval of ADCETRIS), IQNT +2.2% (enters three-year agreement with T-Mobile US (TMUS) for VoIP; raises FY15 rev guidance), IMMU +1.6% (issued a U.S. Patent for a new patent family 'Antibody-SN-38 Immunoconjugates with a CL2A Linker'), ONE +1.5% ( Zilkha Investments discloses 9.7% active stake in 13D filing; may attempt to influence the management of the Company ), JCP +0.9% (favorable commentary on Monday's Mad Money)
Analyst comments: JUNO +2.4% ( initiated with a Outperform at FBR Capital; tgt $73), NNBR +2.2% (initiated with a Buy at Stifel), AEO +0.8% (initiated with a Outperform at Wolfe Research
)